Jubilant Pharmova Ltd

JUBLPHARMA

Watchlist

AI Mode

‌

Market Cap

₹ 17,322 Cr

P/E

34.85

Turned 1 L into 2.62 L in last 3 Years

‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Jubilant Pharmova is a globally integrated pharmaceutical company specializing in radiopharmaceuticals, contract research, and proprietary novel drugs. With a strategic focus on specialty products, its reach spans across geographies from North America to Asia. Key growth drivers include its radiopharmaceutical capabilities, particularly in the U.S., where it holds substantial market share. The company's innovative pursuits are underscored by ongoing clinical trials in precision medicines targeting oncology, with strategic partnerships bolstering its R&D efforts.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

17,322 Cr

Volatility

Moderate Risk

P/E Ratio

34.9

Industry P/E

59.2

PEG Ratio

1.4

P/B Ratio

2.6

52W High

1,250.00

52W Low

823.70

Sales CAGR

7.93%

104.07%

-24.99%

10Y

-13.64%

Profit CAGR

1050.34%

-37.46%

-43.07%

10Y

-13.79%

ROE

TTM

7.25%

5.02%

7.77%

10Y

10.84%

ROCE

TTM

7.77%

6.34%

8.08%

10Y

10.61%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

No. of Analysts

10

1Y Price Target

1417.04 ▲ 33.21%

Q3 EPS Estimate

Q3 Revenue Estimate

Unlock Premium Features

Price, EPS and Revenue Projections

Strong SellSellHoldBuyStrong Buy

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

updated on

Nov 14, 2025

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
NEULANDLAB	16500.00	21,069 Cr	107.61	13.01	0.07	12.09	14.48	9.48
JUBLPHARMA	1087.90	17,322 Cr	34.85	2.63	0.46	7.25	7.77	3.51
ACUTAAS	1630.10	13,350 Cr	59.60	9.44	0.09	15.84	21.30	13.21
GUJTHEM	390.15	4,251 Cr	88.07	16.08	0.17	18.26	19.25	12.82
AARTIDRUGS	391.00	3,582 Cr	18.00	2.44	0.25	13.56	13.12	7.62
HIKAL	250.05	3,090 Cr	305.61	2.59	0.32	0.85	4.28	0.43
SMSPHARMA	323.45	3,035 Cr	35.97	4.16	0.12	11.57	12.36	6.35

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	1,587	1,680	1,677	1,759	1,732	1,752	1,822	1,929	1,901	1,966
Expenses	1,417	1,439	1,459	1,487	1,480	1,463	1,534	1,583	1,611	1,625
Operating Profit	170	242	218	271	252	289	287	345	290	341
OPM %	10.69	14.39	13.00	15.43	14.52	16.52	15.78	17.91	15.24	17.36
Other Income	7.20	19	49	-151	410	7.40	-10	8.50	12	3.90
Interest	62	66	71	73	71	61	56	53	49	50
Depreciation	90	97	95	101	91	91	91	95	98	105
Profit Before Tax	25	98	101	-54	500	144	131	206	154	190
Tax %	76.19	36.63	34.26	-15.08	3.58	29.02	22.84	26.55	33.61	36.99
Net Profit	6.00	62	66	-62	482	103	101	151	103	120
EPS in Rs	0.40	3.94	4.20	-3.68	30.35	6.46	6.36	9.68	6.47	7.57

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	6,006	7,558	9,111	5,976	6,099	6,130	6,282	6,703	7,235	7,404
Expenses	4,516	5,999	7,372	4,428	4,702	4,974	5,506	5,802	6,061	6,192
Operating Profit	1,490	1,558	1,739	1,548	1,396	1,156	776	901	1,174	1,212
OPM %	24.81	20.62	19.09	25.90	22.90	18.86	12.36	13.44	16.22	16.37
Other Income	25	40	-244	4.48	7.66	1.31	-6.20	-76	416	18
Interest	341	284	220	200	184	145	188	272	240	218
Depreciation	291	415	371	340	349	382	554	382	369	376
Profit Before Tax	738	859	904	1,013	871	630	28	171	981	635
Tax %	22.10	26.15	36.16	33.08	34.12	34.49	333.45	57.36	14.72	28.07
Net Profit	575	634	577	678	574	413	-65	73	836	457
EPS in Rs	36.95	41.25	36.86	56.39	52.48	26.00	-3.83	4.86	52.85	30.08
Dividend Payout %	8.13	7.27	12.21	8.87	9.53	19.23	-130.55	102.88	9.46	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	16	16	16	16	16	16	16	16	16	16
Reserves	2,951	3,420	4,071	4,793	5,588	4,726	5,303	5,383	5,418	6,239
Borrowings	3,762	3,761	3,293	4,743	4,570	2,830	3,192	3,677	3,664	2,731
Other Liabilities	2,095	1,844	2,238	1,917	2,348	1,347	1,480	2,081	2,451	3,771
Total Liabilities	8,824	9,041	9,618	11,469	12,522	8,918	9,991	11,157	11,549	12,756
Fixed Assets	5,104	5,107	5,401	5,648	6,340	4,609	4,871	5,183	5,091	5,176
CWIP	611	684	671	901	768	897	1,090	1,562	2,103	3,630
Investments	85	103	124	115	69	241	239	256	42	44
Other Assets	3,023	3,147	3,423	4,804	5,344	3,171	3,792	4,156	4,312	3,907
Total Assets	8,824	9,041	9,618	11,469	12,522	8,918	9,991	11,157	11,549	12,756

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	1,099	1,268	1,303	1,122	1,543	1,784	838	661	971	1,072
Cash from Investing Activity	-309	-465	-614	-1,018	-267	-727	-323	-474	-596	513
Cash from Financing Activity	-843	-686	-901	657	-1,050	-1,709	-33	-157	-433	-1,453
Net Cash Flow	-52	117	-212	761	225	-652	482	30	-58	132

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	50.74%	50.74%	50.97%	50.97%	50.97%	50.97%	50.97%	50.96%	50.96%	50.96%	47.94%	47.98%
FIIs	23.41%	23.25%	23.34%	23.34%	20.41%	19.17%	19.61%	18.04%	17.06%	17.32%	17.50%	16.67%
DIIs	1.63%	2.87%	1.64%	1.66%	2.91%	3.81%	4.09%	5.69%	7.02%	7.08%	9.58%	10.59%
Public	24.22%	23.13%	24.05%	24.02%	25.71%	26.05%	25.33%	25.31%	24.97%	24.64%	24.98%	24.76%
Total Shareholders	1,00,212	97,935	93,375	89,376	86,588	92,264	81,992	89,456	1,02,442	96,526	99,673	93,336

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Oct 01, 2025	Jubilant employees welfare trust	Insider - Trust	Acquisition	1,076.73	1.22 Cr	11,319	0.00
Sep 30, 2025	Jubilant employees welfare trust	Insider - Trust	Acquisition	1,056.37	6.04 Cr	57,181	0.03
Sep 30, 2025	Jubilant employees welfare trust	Insider - Trust	Acquisition	1,039.25	2.08 Cr	20,000	0.01
Sep 30, 2025	Jubilant employees welfare trust	Insider - Trust	Acquisition	1,069.66	5.42 Cr	50,676	0.03
Sep 24, 2025	Jubilant employees welfare trust	Insider - Trust	Acquisition	1,107.83	3.88 Cr	35,000	0.02
Aug 14, 2025	Hsb trustee company private l...	Insider - Promoter Group	Pledge	1,077.50	220.89 Cr	20,50,000	1.28
Aug 14, 2025	Spb trustee company private l...	Insider - Promoter Group	Pledge	1,077.50	220.89 Cr	20,50,000	1.28
Jun 16, 2025	Jubilant enpro private limited	Insider - Promoter Group	Disposal	1,060.00	224.30 Cr	21,16,000	1.33
Jun 16, 2025	Spb trustee company private l...	Insider - Promoter Group	Disposal	1,060.00	74.20 Cr	7,00,000	0.43
Jun 16, 2025	Nikita resources private limited	Insider - Promoter Group	Disposal	1,060.37	208.09 Cr	19,62,434	1.23

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q1 FY25

Showing 1 - 8 of 20

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode